Migraine Drugs Market

ID: MRFR/Pharma/6907-HCR
200 Pages
Nidhi Mandole
Last Updated: April 06, 2026
Migraine Drugs Market Size, Growth Research Report By Drug Type (Abortive Drugs, Preventive Drugs, CGRP Inhibitors, Triptans), By Route of Administration (Oral, Injectable, Nasal), By Therapeutic Class (NSAIDs, Ergots, Beta Blockers, Antidepressants), By Patient Demographics (Adults, Children, Geriatrics), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Competitor Industry Analysis and Trends Forecast Till 2035
Migraine Drugs Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.65%
2024 Market Size$ 5.47 Billion
2025 Market Size$ 5.67 Billion
2035 Market Size$ 8.12 Billion
Key Players
Amgen
Eli Lilly
Teva Pharmaceutical Industries
AbbVie
Boehringer Ingelheim
Pfizer
Trends
  • Emergence of Biologics
  • Integration of Digital Health Solutions
  • Focus on Personalized Medicine
Opportunities
  • Rising Prevalence of Migraine
Summary Table of Contents Segmentation Methodology Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Drug Type (USD Billion)
      1. 4.1.1 Triptans
      2. 4.1.2 Ergots
      3. 4.1.3 CGRP Inhibitors
      4. 4.1.4 Non-Steroidal Anti-Inflammatory Drugs
      5. 4.1.5 Opioids
    2. 4.2 Healthcare, BY Administration Route (USD Billion)
      1. 4.2.1 Oral
      2. 4.2.2 Injectable
      3. 4.2.3 Nasal
      4. 4.2.4 Transdermal
      5. 4.2.5 Intravenous
    3. 4.3 Healthcare, BY Patient Demographics (USD Billion)
      1. 4.3.1 Adults
      2. 4.3.2 Pediatric
      3. 4.3.3 Geriatric
      4. 4.3.4 Gender Specific
      5. 4.3.5 Pregnant Women
    4. 4.4 Healthcare, BY Therapeutic Use (USD Billion)
      1. 4.4.1 Acute Treatment
      2. 4.4.2 Preventive Treatment
      3. 4.4.3 Combination Therapy
      4. 4.4.4 Rescue Therapy
    5. 4.5 Healthcare, BY Region (USD Billion)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Amgen (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Eli Lilly (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Teva Pharmaceutical Industries (IL)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 AbbVie (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Boehringer Ingelheim (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Alder BioPharmaceuticals (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Zogenix (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Novartis (CH)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY DRUG TYPE
    4. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
    5. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    6. 6.6 US MARKET ANALYSIS BY THERAPEUTIC USE
    7. 6.7 CANADA MARKET ANALYSIS BY DRUG TYPE
    8. 6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    9. 6.9 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    10. 6.10 CANADA MARKET ANALYSIS BY THERAPEUTIC USE
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY DRUG TYPE
    13. 6.13 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
    14. 6.14 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    15. 6.15 GERMANY MARKET ANALYSIS BY THERAPEUTIC USE
    16. 6.16 UK MARKET ANALYSIS BY DRUG TYPE
    17. 6.17 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
    18. 6.18 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    19. 6.19 UK MARKET ANALYSIS BY THERAPEUTIC USE
    20. 6.20 FRANCE MARKET ANALYSIS BY DRUG TYPE
    21. 6.21 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
    22. 6.22 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    23. 6.23 FRANCE MARKET ANALYSIS BY THERAPEUTIC USE
    24. 6.24 RUSSIA MARKET ANALYSIS BY DRUG TYPE
    25. 6.25 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    26. 6.26 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    27. 6.27 RUSSIA MARKET ANALYSIS BY THERAPEUTIC USE
    28. 6.28 ITALY MARKET ANALYSIS BY DRUG TYPE
    29. 6.29 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
    30. 6.30 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    31. 6.31 ITALY MARKET ANALYSIS BY THERAPEUTIC USE
    32. 6.32 SPAIN MARKET ANALYSIS BY DRUG TYPE
    33. 6.33 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
    34. 6.34 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    35. 6.35 SPAIN MARKET ANALYSIS BY THERAPEUTIC USE
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG TYPE
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC USE
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY DRUG TYPE
    42. 6.42 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    43. 6.43 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    44. 6.44 CHINA MARKET ANALYSIS BY THERAPEUTIC USE
    45. 6.45 INDIA MARKET ANALYSIS BY DRUG TYPE
    46. 6.46 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    47. 6.47 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    48. 6.48 INDIA MARKET ANALYSIS BY THERAPEUTIC USE
    49. 6.49 JAPAN MARKET ANALYSIS BY DRUG TYPE
    50. 6.50 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
    51. 6.51 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    52. 6.52 JAPAN MARKET ANALYSIS BY THERAPEUTIC USE
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG TYPE
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC USE
    57. 6.57 MALAYSIA MARKET ANALYSIS BY DRUG TYPE
    58. 6.58 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    59. 6.59 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    60. 6.60 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC USE
    61. 6.61 THAILAND MARKET ANALYSIS BY DRUG TYPE
    62. 6.62 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
    63. 6.63 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    64. 6.64 THAILAND MARKET ANALYSIS BY THERAPEUTIC USE
    65. 6.65 INDONESIA MARKET ANALYSIS BY DRUG TYPE
    66. 6.66 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    67. 6.67 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    68. 6.68 INDONESIA MARKET ANALYSIS BY THERAPEUTIC USE
    69. 6.69 REST OF APAC MARKET ANALYSIS BY DRUG TYPE
    70. 6.70 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
    71. 6.71 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    72. 6.72 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC USE
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY DRUG TYPE
    75. 6.75 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
    76. 6.76 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    77. 6.77 BRAZIL MARKET ANALYSIS BY THERAPEUTIC USE
    78. 6.78 MEXICO MARKET ANALYSIS BY DRUG TYPE
    79. 6.79 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
    80. 6.80 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    81. 6.81 MEXICO MARKET ANALYSIS BY THERAPEUTIC USE
    82. 6.82 ARGENTINA MARKET ANALYSIS BY DRUG TYPE
    83. 6.83 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    84. 6.84 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    85. 6.85 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC USE
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC USE
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG TYPE
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC USE
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG TYPE
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC USE
    99. 6.99 REST OF MEA MARKET ANALYSIS BY DRUG TYPE
    100. 6.100 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    101. 6.101 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    102. 6.102 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC USE
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
    111. 6.111 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
    113. 6.113 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
    115. 6.115 HEALTHCARE, BY THERAPEUTIC USE, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY THERAPEUTIC USE, 2024 TO 2035 (USD Billion)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.2.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.3.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.3.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.4.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.4.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.5.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.5.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.6.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.6.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.7.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.7.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.8.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.8.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.9.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.9.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.10.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.10.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.11.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.11.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.12.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.12.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.13.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.13.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.14.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.14.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.15.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.15.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.16.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.16.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.17.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.17.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.18.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.18.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.19.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.19.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.20.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.20.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.21.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.21.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.22.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.22.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.23.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.23.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.24.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.24.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.25.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.25.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.26.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.26.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.27.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.27.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.28.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.28.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.29.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.29.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY DRUG TYPE, 2025-2035 (USD Billion)
      2. 7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      3. 7.30.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.30.4 BY THERAPEUTIC USE, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Migraine Drugs Market Segmentation

Migraine Drugs Market By Drug Type (USD Billion, 2025-2035)

  • Triptans
  • Ergots
  • CGRP Inhibitors
  • Non-Steroidal Anti-Inflammatory Drugs
  • Opioids

Migraine Drugs Market By Administration Route (USD Billion, 2025-2035)

  • Oral
  • Injectable
  • Nasal
  • Transdermal
  • Intravenous

Migraine Drugs Market By Patient Demographics (USD Billion, 2025-2035)

  • Adults
  • Pediatric
  • Geriatric
  • Gender Specific
  • Pregnant Women

Migraine Drugs Market By Therapeutic Use (USD Billion, 2025-2035)

  • Acute Treatment
  • Preventive Treatment
  • Combination Therapy
  • Rescue Therapy

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.